Karyopharm Therapeutics (KPTI)
(Delayed Data from NSDQ)
$0.96 USD
+0.01 (1.43%)
Updated Jul 25, 2024 04:00 PM ET
After-Market: $0.97 +0.01 (1.01%) 7:58 PM ET
2-Buy of 5 2
F Value C Growth B Momentum D VGM
Cash flow Statements
Fiscal Year End for Karyopharm Therapeutics Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -143.10 | -165.29 | -124.09 | -196.27 | -199.59 |
Depreciation/Amortization & Depletion | -2.75 | 0.61 | 3.13 | 10.46 | 6.79 |
Net Change from Assets/Liabilities | 31.42 | -20.27 | -23.19 | 1.36 | -13.31 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 21.72 | 35.40 | 37.03 | 24.22 | 15.29 |
Net Cash From Operating Activities | -92.72 | -149.55 | -107.12 | -160.23 | -190.82 |
Property & Equipment | 0.00 | -0.12 | -0.21 | -0.15 | -0.21 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 7.94 | -104.14 | 147.55 | -53.54 | 78.66 |
Other Investing Activities | 0.00 | 0.00 | -5.50 | 0.00 | 0.00 |
Net Cash from Investing Activities | 7.94 | -104.26 | 141.84 | -53.69 | 78.45 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 1.12 | 193.74 | 13.65 | 172.08 | 50.70 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 73.61 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.00 | 0.00 | 60.00 | 0.00 | 0.00 |
Net Cash from Financing Activities | 1.12 | 193.74 | 73.65 | 172.08 | 124.31 |
Effect of Exchange Rate Changes | -0.03 | -0.49 | -0.05 | 0.27 | 0.02 |
Net Change In Cash & Equivalents | -83.69 | -60.56 | 108.32 | -41.57 | 11.95 |
Cash at Beginning of Period | 136.89 | 197.45 | 89.12 | 130.69 | 118.74 |
Cash at End of Period | 53.19 | 136.89 | 197.45 | 89.12 | 130.69 |
Diluted Net EPS | -1.25 | -2.02 | -1.65 | -2.72 | -3.22 |
Fiscal Year End for Karyopharm Therapeutics Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | NA | -37.36 | -143.10 | -101.26 | -66.76 |
Depreciation/Amortization & Depletion | NA | -0.62 | -2.75 | -2.03 | -1.38 |
Net Change from Assets/Liabilities | NA | -10.72 | 31.42 | 12.62 | 12.07 |
Net Cash from Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | NA | 4.97 | 21.72 | 16.53 | 11.45 |
Net Cash From Operating Activities | NA | -43.73 | -92.72 | -74.14 | -44.61 |
Property & Equipment | NA | -0.20 | 0.00 | 0.00 | 0.00 |
Acquisition/ Disposition of Subsidiaries | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | NA | 22.14 | 7.94 | -18.90 | -11.22 |
Other Investing Activities | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | NA | 21.94 | 7.94 | -18.90 | -11.22 |
Uses of Funds
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | NA | 0.00 | 1.12 | 0.86 | 0.86 |
Issuance (Repayment) of Debt | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Financing Activities | NA | 0.00 | 1.12 | 0.86 | 0.86 |
Effect of Exchange Rate Changes | NA | -0.02 | -0.03 | -0.12 | -0.07 |
Net Change In Cash & Equivalents | NA | -21.80 | -83.69 | -92.30 | -55.04 |
Cash at Beginning of Period | NA | 53.19 | 136.89 | 136.89 | 136.89 |
Cash at End of Period | NA | 31.39 | 53.19 | 44.58 | 81.85 |
Diluted Net EPS | NA | -0.32 | -0.36 | -0.30 | -0.29 |